Trial Profile
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors (Primary) ; Stavudine (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Zidovudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 23 Aug 2020 Results (n=757) of a retrospective, observational cohort of individuals receiving primary care at the vanderbilt comprehensive care clinic and a retrospective analysis of a clinical trials (A5095, A5142 and A5202 and did not receive INSTIs) cohort from efavirenz containing arms of ACTG protocols has been published in the Clinical Infectious Diseases.
- 01 Sep 2017 Results assessing the association between efavirenz metabolizer genotype and suicidality using pooled data from four clinical trials (A5095, A5142 ,A5175, A5202), published in the Journal of Infectious Diseases.
- 16 Feb 2017 Results of pooled analysis of 3 ACTG U.S based randomized trials (A5142, A5202 and A5257) presented at the 24th Conference on Retroviruses and Opportunistic Infections